UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 32

Sortiert nach

2.420 An improved model of L-DOPA-induced dyskinesia in 6-OHDA lesioned rats

Parkinsonism & related disorders, 2007, Vol.13, p.S132-S133

2007

Volltextzugriff (PDF)

BN 80933, a Dual Inhibitor of Neuronal Nitric Oxide Synthase and Lipid Peroxidation: A Promising Neuroprotective Strategy

Proceedings of the National Academy of Sciences - PNAS, 1999-09, Vol.96 (19), p.10824-10829

1999

Volltextzugriff (PDF)

Endothelin receptor subtypes A and B are up-regulated in an experimental model of acute renal failure

Molecular pharmacology, 1994-02, Vol.45 (2), p.182-188

1994

Volltextzugriff (PDF)

In Vitro Antioxidant Neuroprotective Activity of BN 80933, a Dual Inhibitor of Neuronal Nitric Oxide Synthase and Lipid Peroxidation

Journal of neurochemistry, 2000-05, Vol.74 (5), p.2079-2086

2000

Volltextzugriff (PDF)

Somatostatin-14 mainly binds the somatostatin receptor subtype 2 in human neuroblastoma tumors

Neuroendocrinology, 1996-02, Vol.63 (2), p.188

1996

Volltextzugriff (PDF)

Endothelin receptor regulation by endothelin synthesis in vascular smooth muscle cells: effects of dexamethasone and phosphoramidon

Journal of vascular research, 1993-05, Vol.30 (3), p.139

1993

Volltextzugriff (PDF)

Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency

European heart journal, 2015-03, Vol.36 (11), p.657-668

2015

Volltextzugriff (PDF)

Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias

Haematologica (Roma), 2010-04, Vol.95 (4), p.557-566

2010

Volltextzugriff (PDF)

Iron chelation therapy with deferasirox in patients with aplastic anemia: a subgroup analysis of 116 patients from the EPIC trial

Blood, 2010-10, Vol.116 (14), p.2448-2454

2010

Volltextzugriff (PDF)

A9.17 Targeting the Expression of miR-146a in Mouse Inflammatory Ly6C high Monocyte Subset for Therapeutic Intervention in Arthritis

Annals of the rheumatic diseases, 2013-03, Vol.72 (Suppl 1), p.A70-A71

2013

Volltextzugriff (PDF)

A9.17Targeting the Expression of miR-146a in Mouse Inflammatory Ly6Chigh Monocyte Subset for Therapeutic Intervention in Arthritis

Annals of the rheumatic diseases, 2013-03, Vol.72 (Suppl 1), p.A70-A71

2013

Volltextzugriff (PDF)

A9.17 Targeting the Expression of miR-146a in Mouse Inflammatory Ly6Chigh Monocyte Subset for Therapeutic Intervention in Arthritis

Annals of the rheumatic diseases, 2013-03, Vol.72 (Suppl 1), p.A70

2013

Volltextzugriff (PDF)

A4.4MIR-146A deficiency in LY6Chigh monocytes contributes to pathogenic bone loss during inflammatory arthritis

Annals of the rheumatic diseases, 2015-03, Vol.74 (Suppl 1), p.A37-A38

2015

Volltextzugriff (PDF)

A4.4 MIR-146A deficiency in LY6C high monocytes contributes to pathogenic bone loss during inflammatory arthritis

Annals of the rheumatic diseases, 2015-03, Vol.74 (Suppl 1), p.A37-A38

2015

Volltextzugriff (PDF)

Response of iron overload to deferasirox in rare transfusion-dependent anaemias: equivalent effects on serum ferritin and labile plasma iron for haemolytic or production anaemias

European journal of haematology, 2011-10, Vol.87 (4), p.338-348

2011

Volltextzugriff (PDF)

CKD ANAEMIA

Nephrology, dialysis, transplantation, 2014-05, Vol.29 (suppl 3), p.iii21-iii22

2014

Volltextzugriff (PDF)

Increased rewarding properties of morphine in dopamine-transporter knockout mice

The European journal of neuroscience, 2000-05, Vol.12 (5), p.1827-1837

2000

Volltextzugriff (PDF)

Deferasirox for up to 3 years leads to continued improvement of myocardial T2 in patients with -thalassemia major

Haematologica (Roma), 2012-06, Vol.97 (6), p.842-848

2012

Volltextzugriff (PDF)

Continued improvement in myocardial T2 over two years of deferasirox therapy in -thalassemia major patients with cardiac iron overload

Haematologica (Roma), 2011-01, Vol.96 (1), p.48-54

2011

Volltextzugriff (PDF)

410 Antitumoral activity of tasquinimod is mediated through tumour immunomodulatory and antiangiogenic properties in bladder cancer

European urology supplements : official journal of the European Association of Urology, 2014-04, Vol.13 (1), p.e410-e410

2014

Volltextzugriff (PDF)

Angiotensin II and phorbol-esters potently down-regulate endothelin (ET-1) binding sites in vascular smooth muscle cells

Biochemical and biophysical research communications, 1989-10, Vol.164 (2), p.809-815

1989

Volltextzugriff (PDF)

Down-regulation of Endothelin Binding Sites in Rat Vascular Smooth Muscle Cells

American journal of hypertension, 1990-04, Vol.3 (4), p.310-312

1990

Volltextzugriff (PDF)

Binding Characteristics of Endothelin Isoforms (ET-1, ET-2, and ET-3) in Vascular Smooth Muscle Cells

Journal of cardiovascular pharmacology, 1991, Vol.17 Suppl 7, p.S104-108

1991

Volltextzugriff (PDF)

Vascular Mechanism of Action of Endothelin-1: Effect of Ca2+ Antagonists

Journal of cardiovascular pharmacology, 1989, Vol.13 Suppl 5, p.S32-35

1989

Volltextzugriff (PDF)

36 Multiplicity of endothelin receptors in cultured rat aortic smooth muscle cells

Journal of hypertension, 1991-09, Vol.9 (9), p.883

1991

Volltextzugriff (PDF)

1 – 25 von 32

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(27)
Mit Volltextzugriff
(27)

Publikationsform

Artikel
(32)

Sprache

Englisch
(29)
Französisch
(3)

Erscheinungsjahr

n.n

Thema

Science & Technology
(13)
Life Sciences & Biomedicine
(12)
Animals
(11)
Male
(10)
Rats
(9)
Humans
(7)
Biological And Medical Sciences
(6)
Cells, Cultured
(6)
Receptors, Endothelin
(6)
Kinetics
(5)
Muscle, Smooth, Vascular - Metabolism
(5)
Cardiovascular System & Cardiology
(4)
Endothelins - Metabolism
(4)
Female
(4)
Rats, Inbred Strains
(4)
Receptors, Cell Surface - Metabolism
(4)
Adolescent
(3)
Endothelin
(3)
Endothelins
(3)
Ferritins - Blood
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

2.420 An improved model of L-DOPA-induced dyskinesia in 6-OHDA lesioned rats

BN 80933, a Dual Inhibitor of Neuronal Nitric Oxide Synthase and Lipid Peroxidation: A Promising Neuroprotective Strategy

Endothelin receptor subtypes A and B are up-regulated in an experimental model of acute renal failure

In Vitro Antioxidant Neuroprotective Activity of BN 80933, a Dual Inhibitor of Neuronal Nitric Oxide Synthase and Lipid Peroxidation

Somatostatin-14 mainly binds the somatostatin receptor subtype 2 in human neuroblastoma tumors

Endothelin receptor regulation by endothelin synthesis in vascular smooth muscle cells: effects of dexamethasone and phosphoramidon

Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency

Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias

Iron chelation therapy with deferasirox in patients with aplastic anemia: a subgroup analysis of 116 patients from the EPIC trial

A9.17 Targeting the Expression of miR-146a in Mouse Inflammatory Ly6C high Monocyte Subset for Therapeutic Intervention in Arthritis

A9.17Targeting the Expression of miR-146a in Mouse Inflammatory Ly6Chigh Monocyte Subset for Therapeutic Intervention in Arthritis

A9.17 Targeting the Expression of miR-146a in Mouse Inflammatory Ly6Chigh Monocyte Subset for Therapeutic Intervention in Arthritis

A4.4MIR-146A deficiency in LY6Chigh monocytes contributes to pathogenic bone loss during inflammatory arthritis

A4.4 MIR-146A deficiency in LY6C high monocytes contributes to pathogenic bone loss during inflammatory arthritis

Response of iron overload to deferasirox in rare transfusion-dependent anaemias: equivalent effects on serum ferritin and labile plasma iron for haemolytic or production anaemias

CKD ANAEMIA

Increased rewarding properties of morphine in dopamine-transporter knockout mice

Deferasirox for up to 3 years leads to continued improvement of myocardial T2 in patients with -thalassemia major

Continued improvement in myocardial T2 over two years of deferasirox therapy in -thalassemia major patients with cardiac iron overload

410 Antitumoral activity of tasquinimod is mediated through tumour immunomodulatory and antiangiogenic properties in bladder cancer

Angiotensin II and phorbol-esters potently down-regulate endothelin (ET-1) binding sites in vascular smooth muscle cells

Down-regulation of Endothelin Binding Sites in Rat Vascular Smooth Muscle Cells

Binding Characteristics of Endothelin Isoforms (ET-1, ET-2, and ET-3) in Vascular Smooth Muscle Cells

Vascular Mechanism of Action of Endothelin-1: Effect of Ca2+ Antagonists

36 Multiplicity of endothelin receptors in cultured rat aortic smooth muscle cells

Suchergebnisse filtern